



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

July 2019





HIV/AIDS Drug Treatment Program

Monthly Report

© 2019 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

July 2019

N = 7397



Health Authority	Male	Female	All
FRASER	1447	423	1870
INTERIOR	417	96	513
NORTHERN	136	82	218
VANCOUVER COASTAL	3395	446	3841
VANCOUVER ISLAND	764	157	921
	6159	1204	7363
		Unknown/not stated:	34
		Total:	7397

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (July 2014 - July 2019)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (July 2014 - July 2019)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (July 2014 - July 2019)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (July 2014 - July 2019)






1.6 Percent Distribution of Active Participants by CD4 Count (July 2014 - July 2019)






1.7 Percent Distribution of Inactive Participants by CD4 Count (July 2014 - July 2019)






1.8 Active and Inactive Participants (July 2014 - July 2019)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (July 2014 - July 2019)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (July 2014 - July 2019)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(July 2014 - July 2019)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (July 2014 - July 2019)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT (July 2014 - July 2019)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (July 2014 - July 2019)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(July 2014 - July 2019)





1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (July 2014 - July 2019)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(July 2014 - July 2019)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes






1.18 Baseline CD4 for Antiretroviral First Starts (July 2014 - July 2019)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (July 2014 - July 2019)






1.20 Cumulative Resistance Testing Results by Resistance Category (July 2014 - July 2019)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (July 2014 - July 2019)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2019
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	27	5	0	5	2	650	5	<40	3
1988	28	6	0	6	5	400	6	<40	3
1989	26	52	1	53	41	500	50	<40	3
1990	25	54	1	55	41	560	54	<40	3
1991	25	38	3	41	28	580	40	<40	3
1992	25	63	5	68	45	560	65	<40	3
1993	24	135	16	151	132	555	146	<40	3
1994	23	82	13	95	74	500	92	<40	3
1995	22	134	22	156	123	560	147	<40	3
1996	20	343	55	398	317	580	376	<40	3
1997	19	292	32	324	266	650	308	<40	3
1998	18	199	39	238	186	550	222	<40	3
1999	18	163	40	203	156	560	188	<40	3
2000	18	125	33	158	124	590	146	<40	3
2001	18	122	29	151	117	560	140	<40	3
2002	16	128	27	155	126	545	150	<40	3
2003	16	158	31	189	148	590	180	<40	3
2004	15	160	39	199	162	590	190	<40	3
2005	14	189	45	234	191	630	222	<40	3
2006	13	190	41	231	186	605	219	<40	3
2007	12	257	49	306	246	625	286	<40	3
2008	11	293	71	364	294	640	346	<40	3
2009	10	321	67	388	313	660	369	<40	3
2010	9	287	74	361	298	650	343	<40	3
2011	8	327	74	401	320	688	373	<40	3
2012	7	278	64	342	274	710	320	<40	3
2013	6	270	67	337	268	660	319	<40	3
2014	5	285	53	338	266	700	317	<40	3
2015	4	296	50	346	273	660	322	<40	3
2016	3	283	50	333	255	640	308	<40	3
2017	2	241	36	277	235	640	266	<40	3
2018	1	226	55	281	228	623	274	<40	3
2019	0	159	29	188	173	560	184	<40	3
Total:		6161	1211	7372					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	7281	750	2385	<40	2109	610
FEB-2018	7245	763	1904	<40	1743	610
MAR-2018	7270	769	2050	<40	1831	617
APR-2018	7256	776	2080	<40	1842	620
MAY-2018	7274	773	2147	<40	1928	600
JUN-2018	7274	787	2003	<40	1786	610
JUL-2018	7284	785	2037	<40	1810	600
AUG-2018	7289	795	2092	<40	1873	620
SEP-2018	7244	795	2015	<40	1787	620
OCT-2018	7338	776	2170	<40	1945	610
NOV-2018	7341	781	2091	<40	1813	630
DEC-2018	7358	788	1747	<40	1534	620
JAN-2019	7398	792	2456	<40	2139	610
FEB-2019	7381	799	1853	<40	1572	620
MAR-2019	7422	790	2086	<40	1742	610
APR-2019	7378	793	2143	<40	1726	610
MAY-2019	7435	795	2127	<40	1722	620
JUN-2019	7391	803	1928	<40	1514	610
JUL-2019	7397	812	2113	<40	1591	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	1428	3315	79	890	71	380
FEB-2018	1472	3112	79	1036	66	440
MAR-2018	1456	3198	75	59	70	485
APR-2018	1474	3163	73	459	63	497
MAY-2018	1462	3229	93	<40	82	455
JUN-2018	1472	3230	73	1080	70	440
JUL-2018	1472	3261	70	<40	55	570
AUG-2018	1501	3172	64	63	60	485
SEP-2018	1546	2985	88	220	82	410
OCT-2018	1473	3335	79	<50	69	350
NOV-2018	1485	3311	82	87	74	480
DEC-2018	1481	3343	57	355	46	495
JAN-2019	1470	3415	73	73	65	350
FEB-2019	1498	3331	75	108	66	590
MAR-2019	1462	3504	74	885	61	400
APR-2019	1498	3392	79	<50	69	500
MAY-2019	1446	3624	78	87	66	455
JUN-2019	1495	3456	76	<40	63	500
JUL-2019	1487	3513	69	<40	57	530

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2018	7242	1428	12	12	193	127	56	13217
FEB-2018	7211	1472	11	27	125	169	-31	13254
MAR-2018	7231	1456	17	21	158	138	20	13281
APR-2018	7223	1474	12	15	154	161	-8	13303
MAY-2018	7244	1462	9	12	174	153	21	13328
JUN-2018	7240	1472	13	16	152	156	-4	13350
JUL-2018	7242	1472	13	13	165	155	2	13376
AUG-2018	7253	1501	9	27	158	159	11	13415
SEP-2018	7207	1546	14	15	155	195	-46	13441
OCT-2018	7306	1473	8	19	218	126	99	13477
NOV-2018	7314	1485	5	9	171	164	8	13503
DEC-2018	7330	1481	11	19	152	142	16	13528
JAN-2019	7365	1470	14	20	191	159	35	13563
FEB-2019	7353	1498	7	16	161	179	-12	13592
MAR-2019	7380	1462	15	13	188	147	27	13612
APR-2019	7338	1498	10	16	150	179	-42	13640
MAY-2019	7403	1446	10	21	195	137	65	13682
JUN-2019	7360	1495	14	15	136	179	-43	13703
JUL-2019	7372	1487	12	13	173	160	12	13726

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2018	60	6718	448	55	7281	0.82%	92.27%	6.15%	0.76%	100.00%
FEB-2018	64	6672	450	59	7245	0.88%	92.09%	6.21%	0.81%	100.00%
MAR-2018	62	6699	453	56	7270	0.85%	92.15%	6.23%	0.77%	100.00%
APR-2018	62	6688	449	57	7256	0.85%	92.17%	6.19%	0.79%	100.00%
MAY-2018	69	6692	455	58	7274	0.95%	92.00%	6.26%	0.80%	100.00%
JUN-2018	62	6708	447	57	7274	0.85%	92.22%	6.15%	0.78%	100.00%
JUL-2018	53	6718	458	55	7284	0.73%	92.23%	6.29%	0.76%	100.00%
AUG-2018	56	6723	454	56	7289	0.77%	92.23%	6.23%	0.77%	100.00%
SEP-2018	55	6676	456	57	7244	0.76%	92.16%	6.29%	0.79%	100.00%
OCT-2018	54	6756	474	54	7338	0.74%	92.07%	6.46%	0.74%	100.00%
NOV-2018	53	6763	475	50	7341	0.72%	92.13%	6.47%	0.68%	100.00%
DEC-2018	52	6780	477	49	7358	0.71%	92.14%	6.48%	0.67%	100.00%
JAN-2019	54	6805	486	53	7398	0.73%	91.98%	6.57%	0.72%	100.00%
FEB-2019	52	6788	492	49	7381	0.70%	91.97%	6.67%	0.66%	100.00%
MAR-2019	59	6823	490	50	7422	0.79%	91.93%	6.60%	0.67%	100.00%
APR-2019	56	6784	490	48	7378	0.76%	91.95%	6.64%	0.65%	100.00%
MAY-2019	55	6843	492	45	7435	0.74%	92.04%	6.62%	0.61%	100.00%
JUN-2019	56	6804	483	48	7391	0.76%	92.06%	6.53%	0.65%	100.00%
JUL-2019	58	6800	491	48	7397	0.78%	91.93%	6.64%	0.65%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>																	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All																
JAN-2018	10	36%	3314	47%	9	32%	3070	43%	1	4%	61	1%	0	0%	5	0%	0	0%	4	0%	2	7%	292	4%	16	57%	3628	51%		
FEB-2018	13	35%	3315	47%	12	32%	3073	44%	0	0%	61	1%	0	0%	5	0%	0	0%	4	0%	0	0%	299	4%	25	68%	3578	51%		
MAR-2018	10	37%	3334	47%	10	37%	3099	44%	0	0%	59	1%	0	0%	4	0%	0	0%	4	0%	0	0%	311	4%	17	63%	3564	50%		
APR-2018	5	23%	3342	47%	5	23%	3111	44%	0	0%	55	1%	0	0%	3	0%	0	0%	4	0%	2	9%	333	5%	15	68%	3533	50%		
MAY-2018	9	39%	3351	48%	8	35%	3125	44%	1	4%	57	1%	0	0%	5	0%	0	0%	4	0%	1	4%	351	5%	13	57%	3504	50%		
JUN-2018	7	35%	3365	48%	7	35%	3142	45%	0	0%	53	1%	0	0%	5	0%	0	0%	3	0%	1	5%	379	5%	12	60%	3473	49%		
JUL-2018	7	28%	3394	48%	7	28%	3172	45%	0	0%	51	1%	0	0%	5	0%	0	0%	3	0%	4	16%	398	6%	14	56%	3444	49%		
AUG-2018	13	33%	3393	48%	14	36%	3181	45%	0	0%	50	1%	0	0%	4	0%	0	0%	3	0%	2	5%	415	6%	23	59%	3413	48%		
SEP-2018	4	15%	3377	48%	3	12%	3162	45%	1	4%	47	1%	0	0%	4	0%	0	0%	4	0%	2	0%	4	15%	446	6%	18	69%	3364	48%
OCT-2018	11	31%	3418	48%	9	26%	3205	45%	1	3%	49	1%	0	0%	3	0%	0	0%	3	0%	2	0%	0	0%	479	7%	25	71%	3382	47%
NOV-2018	9	35%	3428	48%	8	31%	3214	45%	0	0%	47	1%	0	0%	4	0%	0	0%	4	0%	2	0%	1	4%	491	7%	17	65%	3351	47%
DEC-2018	8	32%	3446	48%	8	32%	3233	45%	0	0%	45	1%	0	0%	4	0%	0	0%	1	0%	2	8%	504	7%	15	60%	3348	47%		
JAN-2019	8	23%	3471	48%	7	20%	3258	45%	1	3%	45	1%	0	0%	4	0%	0	0%	1	0%	1	3%	519	7%	26	74%	3360	47%		
FEB-2019	13	45%	3465	48%	12	41%	3264	45%	0	0%	44	1%	0	0%	1	0%	0	0%	1	0%	3	10%	542	8%	13	45%	3311	46%		
MAR-2019	6	30%	3479	48%	6	30%	3282	45%	0	0%	43	1%	0	0%	2	0%	0	0%	0	0%	2	10%	559	8%	12	60%	3313	46%		
APR-2019	12	43%	3480	48%	12	43%	3288	46%	0	0%	43	1%	0	0%	2	0%	0	0%	0	0%	2	7%	586	8%	14	50%	3255	45%		
MAY-2019	14	34%	3511	49%	14	34%	3319	46%	0	0%	43	1%	0	0%	2	0%	0	0%	1	0%	4	10%	593	8%	23	56%	3266	45%		
JUN-2019	3	14%	3495	49%	3	14%	3307	46%	0	0%	43	1%	0	0%	2	0%	0	0%	1	0%	2	10%	610	8%	16	76%	3213	45%		
JUL-2019	8	35%	3518	49%	8	35%	3337	46%	0	0%	39	1%	0	0%	2	0%	0	0%	1	0%	1	4%	624	9%	14	61%	3191	44%		

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2018	18	64%	3704	52%
FEB-2018	24	65%	3672	52%
MAR-2018	17	63%	3670	52%
APR-2018	17	77%	3655	52%
MAY-2018	14	61%	3650	52%
JUN-2018	13	65%	3650	52%
JUL-2018	18	72%	3647	52%
AUG-2018	25	64%	3646	52%
SEP-2018	22	85%	3624	51%
OCT-2018	24	69%	3683	52%
NOV-2018	17	65%	3667	51%
DEC-2018	17	68%	3669	51%
JAN-2019	27	77%	3699	51%
FEB-2019	16	55%	3680	51%
MAR-2019	14	70%	3709	51%
APR-2019	16	57%	3671	51%
MAY-2019	27	66%	3695	51%
JUN-2019	18	86%	3660	51%
JUL-2019	15	65%	3666	51%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	8 0%	3 30%	1313 45%	7 70%	1414 48%	0 0%	195 7%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
FEB-2018	0 0%	6 0%	0 0%	1255 44%	15 100%	1420 49%	0 0%	189 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAR-2018	0 0%	7 0%	1 9%	1243 43%	10 91%	1438 50%	0 0%	187 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
APR-2018	0 0%	6 0%	0 0%	1220 43%	11 100%	1435 50%	0 0%	180 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2018	0 0%	7 0%	0 0%	1204 42%	5 100%	1438 51%	0 0%	181 6%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JUN-2018	0 0%	7 0%	1 8%	1185 42%	11 92%	1428 51%	0 0%	175 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
JUL-2018	0 0%	7 0%	2 20%	1168 42%	7 70%	1438 52%	1 10%	168 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
AUG-2018	0 0%	7 0%	5 31%	1155 42%	11 69%	1422 52%	0 0%	166 6%	0 0%	1 0%	0 0%	1 0%	0 0%	8 0%
SEP-2018	0 0%	7 0%	1 14%	1132 42%	6 86%	1404 52%	0 0%	159 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
OCT-2018	0 0%	7 0%	3 17%	1121 41%	15 83%	1445 53%	0 0%	153 6%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
NOV-2018	0 0%	6 0%	1 14%	1116 41%	6 86%	1456 53%	0 0%	146 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
DEC-2018	0 0%	5 0%	1 11%	1106 41%	7 78%	1457 54%	1 11%	145 5%	0 0%	0 0%	0 0%	2 0%	0 0%	9 0%
JAN-2019	0 0%	6 0%	1 8%	1098 40%	11 92%	1478 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
FEB-2019	0 0%	5 0%	2 18%	1071 40%	9 82%	1475 55%	0 0%	138 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
MAR-2019	0 0%	5 0%	2 40%	1054 39%	3 60%	1487 55%	0 0%	133 5%	0 0%	1 0%	0 0%	1 0%	0 0%	7 0%
APR-2019	0 0%	5 0%	1 10%	1030 39%	7 70%	1479 56%	2 20%	133 5%	0 0%	2 0%	0 0%	1 0%	0 0%	7 0%
MAY-2019	0 0%	5 0%	1 8%	1034 39%	11 92%	1482 56%	0 0%	130 5%	0 0%	2 0%	0 0%	1 0%	0 0%	6 0%
JUN-2019	0 0%	5 0%	0 0%	1007 39%	9 100%	1472 57%	0 0%	120 5%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JUL-2019	0 0%	5 0%	0 0%	986 38%	7 100%	1487 57%	0 0%	113 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2018	0	0%	1	0%
FEB-2018	0	0%	1	0%
MAR-2018	0	0%	1	0%
APR-2018	0	0%	1	0%
MAY-2018	0	0%	1	0%
JUN-2018	0	0%	1	0%
JUL-2018	0	0%	1	0%
AUG-2018	0	0%	1	0%
SEP-2018	0	0%	1	0%
OCT-2018	0	0%	1	0%
NOV-2018	0	0%	1	0%
DEC-2018	0	0%	1	0%
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%
MAY-2019	0	0%	1	0%
JUN-2019	0	0%	1	0%
JUL-2019	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	0 0%	3 50%	778 37%	1 17%	262 12%	2 33%	757 36%	0 0%	302 14%
FEB-2018	0 0%	0 0%	3 75%	769 37%	0 0%	257 12%	0 0%	749 36%	1 25%	306 15%
MAR-2018	0 0%	0 0%	1 33%	757 37%	0 0%	250 12%	0 0%	736 36%	2 67%	311 15%
APR-2018	0 0%	0 0%	1 50%	745 37%	0 0%	245 12%	0 0%	731 36%	1 50%	318 16%
MAY-2018	0 0%	0 0%	4 67%	725 36%	1 17%	252 12%	0 0%	727 36%	1 17%	316 16%
JUN-2018	0 0%	0 0%	1 50%	720 36%	0 0%	248 12%	0 0%	724 36%	1 50%	313 16%
JUL-2018	0 0%	0 0%	3 60%	721 36%	0 0%	243 12%	0 0%	717 36%	2 40%	313 16%
AUG-2018	0 0%	0 0%	2 100%	714 36%	0 0%	238 12%	0 0%	716 36%	0 0%	308 16%
SEP-2018	0 0%	0 0%	6 100%	706 36%	0 0%	236 12%	0 0%	712 36%	0 0%	311 16%
OCT-2018	0 0%	0 0%	3 60%	696 36%	0 0%	234 12%	0 0%	710 36%	2 40%	323 16%
NOV-2018	0 0%	0 0%	8 80%	687 35%	0 0%	230 12%	0 0%	700 36%	2 20%	322 17%
DEC-2018	0 0%	0 0%	1 100%	684 36%	0 0%	225 12%	0 0%	696 36%	0 0%	319 17%
JAN-2019	0 0%	0 0%	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	0 0%	0 0%	2 67%	668 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	0 0%	0 0%	3 75%	660 35%	0 0%	224 12%	1 25%	681 36%	0 0%	322 17%
APR-2019	0 0%	0 0%	4 100%	646 35%	0 0%	223 12%	0 0%	678 36%	0 0%	320 17%
MAY-2019	0 0%	0 0%	5 100%	648 35%	0 0%	219 12%	0 0%	672 36%	0 0%	322 17%
JUN-2019	0 0%	0 0%	3 75%	635 35%	0 0%	211 12%	0 0%	664 36%	1 25%	320 18%
JUL-2019	0 0%	1 0%	2 100%	635 35%	0 0%	211 12%	0 0%	657 36%	0 0%	323 18%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	0 0%	9 47%	2003 60%	8 42%	630 19%	0 0%	46 1%	2 11%	685 21%
FEB-2018	0 0%	0 0%	16 70%	2023 60%	6 26%	640 19%	0 0%	45 1%	1 4%	675 20%
MAR-2018	0 0%	0 0%	14 100%	2058 61%	0 0%	645 19%	0 0%	43 1%	0 0%	674 20%
APR-2018	0 0%	0 0%	8 67%	2102 61%	4 33%	653 19%	0 0%	44 1%	0 0%	681 20%
MAY-2018	0 0%	0 0%	13 65%	2136 61%	4 20%	664 19%	1 5%	42 1%	3 15%	675 19%
JUN-2018	0 0%	0 0%	8 73%	2168 62%	2 18%	672 19%	0 0%	42 1%	1 9%	676 19%
JUL-2018	0 0%	0 0%	7 58%	2202 62%	4 33%	674 19%	0 0%	42 1%	1 8%	675 19%
AUG-2018	0 0%	0 0%	23 79%	2252 62%	5 17%	675 19%	0 0%	42 1%	1 3%	671 19%
SEP-2018	0 0%	9 0%	5 36%	2261 62%	9 64%	689 19%	0 0%	41 1%	0 0%	655 18%
OCT-2018	0 0%	17 0%	13 76%	2318 63%	4 24%	708 19%	0 0%	40 1%	0 0%	658 18%
NOV-2018	0 0%	17 0%	11 100%	2344 63%	0 0%	703 19%	0 0%	38 1%	0 0%	650 17%
DEC-2018	0 0%	17 0%	13 76%	2367 63%	4 24%	719 19%	0 0%	39 1%	0 0%	652 17%
JAN-2019	0 0%	16 0%	15 75%	2430 63%	4 20%	730 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2438 63%	5 23%	727 19%	0 0%	40 1%	1 5%	653 17%
MAR-2019	0 0%	27 1%	8 62%	2488 64%	5 38%	747 19%	0 0%	38 1%	0 0%	647 17%
APR-2019	0 0%	27 1%	8 57%	2503 64%	3 21%	739 19%	0 0%	36 1%	3 21%	637 16%
MAY-2019	0 0%	27 1%	19 68%	2566 64%	6 21%	749 19%	0 0%	37 1%	3 11%	636 16%
JUN-2019	0 0%	27 1%	10 77%	2571 65%	3 23%	748 19%	0 0%	37 1%	0 0%	625 16%
JUL-2019	0 0%	27 1%	14 82%	2615 65%	3 18%	759 19%	0 0%	38 1%	0 0%	628 16%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2018	2004	27.52	1644	22.58	2592	35.60	117	1.61	55	0.76	869	11.94
FEB-2018	1961	27.07	1629	22.48	2610	36.02	116	1.60	59	0.81	870	12.01
MAR-2018	1974	27.15	1615	22.21	2644	36.37	113	1.55	56	0.77	868	11.94
APR-2018	1928	26.57	1596	22.00	2696	37.16	114	1.57	57	0.79	865	11.92
MAY-2018	1918	26.37	1575	21.65	2733	37.57	114	1.57	58	0.80	876	12.04
JUN-2018	1903	26.16	1562	21.47	2785	38.29	113	1.55	57	0.78	854	11.74
JUL-2018	1886	25.89	1565	21.49	2814	38.63	110	1.51	55	0.76	854	11.72
AUG-2018	1860	25.52	1549	21.25	2860	39.24	111	1.52	56	0.77	853	11.70
SEP-2018	1823	25.17	1532	21.15	2878	39.73	109	1.50	57	0.79	845	11.66
OCT-2018	1848	25.18	1529	20.84	2946	40.15	104	1.42	54	0.74	857	11.68
NOV-2018	1842	25.09	1522	20.73	2966	40.40	106	1.44	50	0.68	855	11.65
DEC-2018	1835	24.94	1510	20.52	3005	40.84	104	1.41	49	0.67	855	11.62
JAN-2019	1833	24.78	1481	20.02	3063	41.40	100	1.35	53	0.72	868	11.73
FEB-2019	1805	24.45	1479	20.04	3081	41.74	99	1.34	49	0.66	868	11.76
MAR-2019	1795	24.18	1473	19.85	3135	42.24	99	1.33	50	0.67	870	11.72
APR-2019	1763	23.90	1461	19.80	3148	42.67	101	1.37	48	0.65	857	11.62
MAY-2019	1775	23.87	1449	19.49	3211	43.19	97	1.30	45	0.61	858	11.54
JUN-2019	1751	23.69	1440	19.48	3214	43.49	95	1.29	48	0.65	843	11.41
JUL-2019	1721	23.27	1429	19.32	3252	43.96	92	1.24	48	0.65	855	11.56

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2018	12	1	1	0	4	4	470
FEB-2018	27	3	2	2	6	13	485
MAR-2018	21	4	1	5	4	6	325
APR-2018	15	0	0	5	3	5	480
MAY-2018	12	1	0	4	3	2	370
JUN-2018	16	3	5	1	1	6	237
JUL-2018	13	4	1	3	4	1	284
AUG-2018	27	2	2	6	4	13	450
SEP-2018	15	2	3	1	3	5	405
OCT-2018	19	0	1	2	5	10	525
NOV-2018	9	2	2	2	0	2	185
DEC-2018	19	2	0	5	5	7	380
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	16	3	3	1	3	4	368
MAY-2019	21	1	0	6	8	4	440
JUN-2019	15	2	1	1	2	7	510
JUL-2019	13	1	1	1	3	7	530

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2018	11955	3651
FEB-2018	11985	3666
MAR-2018	12013	3696
APR-2018	12045	3726
MAY-2018	12080	3751
JUN-2018	12092	3754
JUL-2018	12118	3778
AUG-2018	12132	3773
SEP-2018	12155	3794
OCT-2018	12174	3794
NOV-2018	12211	3813
DEC-2018	12215	3808
JAN-2019	12255	3833
FEB-2019	12263	3832
MAR-2019	12293	3862
APR-2019	12320	3886
MAY-2019	12337	3887
JUN-2019	12337	3892
JUL-2019	12360	3912

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
July 2019

N = 7397

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2019

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2019

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2019

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2019

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2019

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





**4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
INTERIOR Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	6	6	*
	35-49	11	13	*
	50+	26	37	*
	Total HSDA:	43	56	28
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	73	97	54	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	367	493	286	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	12
	35-49	*	*	44
	50+	*	*	89
Total HSDA:	191	256	145	
Total HA:		674	902	513

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	*
	20-34	63	64	*
	35-49	177	198	*
	50+	429	635	*
Total HA:		674	902	513

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	538	723	417
Female	136	179	96

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	513	55	610	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	11
	5 years or more	11	6
	<5 years	14	11
	Total HSDA:	43	28
KOOTENAY BOUNDARY	10 years or more	44	31
	5 years or more	16	12
	<5 years	13	11
	Total HSDA:	73	54
OKANAGAN	10 years or more	229	170
	5 years or more	65	54
	<5 years	73	62
	Total HSDA:	367	286
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	107	77
	5 years or more	40	34
	<5 years	44	34
	Total HSDA:	191	145
Total HA:		674	513

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	398	289
	5 years or more	132	106
	<5 years	144	118
Total HA:		674	513

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	41	59	12	25
KOOTENAY BOUNDARY	69	121	18	42
OKANAGAN	213	915	56	283
THOMPSON/CARIBOO/SHUSWAP	132	504	38	133
Total:	455	1599	124	483

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	99

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	7
	20-34	28	30	20
	35-49	106	116	84
	50+	232	306	185
	Total HSDA:	373	459	296
FRASER NORTH	0-19	10	10	*
	20-34	104	105	*
	35-49	356	388	*
	50+	539	861	*
	Total HSDA:	1009	1364	763
FRASER SOUTH	0-19	7	7	*
	20-34	120	122	*
	35-49	334	380	*
	50+	530	782	*
	Total HSDA:	991	1291	811
Total HA:		2373	3114	1870

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	24	24	13
	20-34	252	257	176
	35-49	796	884	628
	50+	1301	1949	1053
Total HA:		2373	3114	1870

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1804	2389	1447
Female	569	725	423

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1870	51	630	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	212	168
	5 years or more	79	63
	<5 years	82	65
	Total HSDA:	373	296
FRASER NORTH	10 years or more	554	394
	5 years or more	249	198
	<5 years	206	171
	Total HSDA:	1009	763
FRASER SOUTH	10 years or more	539	435
	5 years or more	221	176
	<5 years	231	200
	Total HSDA:	991	811
Total HA:		2373	1870

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1305	997
	5 years or more	549	437
	<5 years	519	436
Total HA:		2373	1870

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	140	490	31	65
FRASER NORTH	248	1555	46	236
FRASER SOUTH	212	1447	45	456
Total:	600	3492	122	757

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	202
FRASER NORTH	637
FRASER SOUTH	502
Total:	1341

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	19
	35-49	*	*	61
	50+	*	*	200
	Total HSDA:		332	479
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		174	223
VANCOUVER	0-19	35	35	7
	20-34	439	453	320
	35-49	1389	1571	1014
	50+	2788	4752	2083
	Total HSDA:	4651	6811	3424
Total HA:		5157	7513	3841

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	38	38	8
	20-34	490	505	357
	35-49	1512	1706	1110
	50+	3117	5264	2366
Total HA:		5157	7513	3841

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4548	6596	3395
Female	607	915	446

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3841	53	630	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	183	151
	5 years or more	87	77
	<5 years	62	52
	Total HSDA:	332	280
RICHMOND	10 years or more	99	74
	5 years or more	38	32
	<5 years	37	31
	Total HSDA:	174	137
VANCOUVER	10 years or more	2701	1926
	5 years or more	1184	862
	<5 years	766	636
	Never on ART	0	0
	Total HSDA:	4651	3424
Total HA:	5157	3841	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2983	2151
5 years or more	1309	971
<5 years	865	719
Never on ART	0	0
Total HA:	5157	3841

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	168	490	51	175
RICHMOND	43	287	12	96
VANCOUVER	593	10728	193	5298
Total:	804	11505	256	5569

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	105

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		321	453
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		124	166
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		723	1026
Total HA:		1168	1645	921

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	*
	20-34	105	112	*
	35-49	308	358	*
	50+	748	1168	*
Total HA:		1168	1645	921

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	960	1352	764
Female	208	293	157

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	921	54	540	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	173	145
	5 years or more	69	55
	<5 years	79	64
	Total HSDA:	321	264
NORTH VANCOUVER ISLAND	10 years or more	71	57
	5 years or more	30	22
	<5 years	23	20
	Total HSDA:	124	99
SOUTH VANCOUVER ISLAND	10 years or more	420	299
	5 years or more	154	130
	<5 years	149	129
	Total HSDA:	723	558
Total HA:		1168	921

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	664	501
	5 years or more	253	207
	<5 years	251	213
Total HA:		1168	921

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	191	853	72	196
NORTH VANCOUVER ISLAND	136	263	48	79
SOUTH VANCOUVER ISLAND	208	1768	42	553
Total:	535	2884	162	828

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	52
NORTH VANCOUVER ISLAND	37
SOUTH VANCOUVER ISLAND	105
Total:	194

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		41	49
NORTH WEST	0-19	*	*	0
	20-34	*	*	7
	35-49	*	*	15
	50+	*	*	34
	Total HSDA:		69	107
NORTHERN INTERIOR	0-19	5	5	*
	20-34	21	23	*
	35-49	72	89	*
	50+	87	147	*
	Total HSDA:		185	264
Total HA:		295	420	218

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	*
	20-34	34	37	*
	35-49	110	147	*
	50+	144	229	*
Total HA:		295	420	218

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	179	260	136
Female	116	160	82

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	218	51	560	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	20	*
	5 years or more	13	*
	<5 years	8	*
	Total HSDA:	41	22
NORTH WEST	10 years or more	32	24
	5 years or more	24	21
	<5 years	13	11
	Total HSDA:	69	56
NORTHERN INTERIOR	10 years or more	74	53
	5 years or more	60	51
	<5 years	51	36
	Total HSDA:	185	140
Total HA:		295	218

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	126	86
5 years or more	97	81
<5 years	72	51
Total HA:	295	218

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	39	63	7	8
NORTH WEST	71	161	13	31
NORTHERN INTERIOR	105	459	15	180
Total:	215	683	35	219

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	20
NORTHERN INTERIOR	17
Total:	43

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	22	38	*
	THOMPSON/CARIBOO/SHUSWAP	26	45	*
	Total HA:	60	102	41
FRASER	FRASER EAST	45	55	37
	FRASER NORTH	53	89	42
	FRASER SOUTH	71	104	53
	Total HA:	169	248	132
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	26	49	24
	RICHMOND	12	17	10
	VANCOUVER	487	852	388
	Total HA:	525	918	422
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	79	43
	NORTH VANCOUVER ISLAND	17	26	15
	SOUTH VANCOUVER ISLAND	36	79	29
	Total HA:	104	184	87
NORTHERN	NORTH EAST	10	12	6
	NORTH WEST	29	58	24
	NORTHERN INTERIOR	69	106	56
	Total HA:	108	176	86
Total:		966	1628	768

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	602	1036	482
Female	364	592	286

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	768	51	480	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by





blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

